Zydus Lifesciences informed exchanges on Tuesday that it has received a warning notice from the USFDA regarding its injectables manufacturing facility at Jarod near Vadodara.

The USFDA’s Warning Letter states the concern, which may include gaps in manufacturing practices or breaches of current good manufacturing standards (cGMP).

In the exchange filing, the company shared, “Zydus has received this letter for the injectable manufacturing facility situated at Jarod, near Vadodara, Gujarat. The letter provides an opportunity to the company to address USFDA’s concerns, and it requests a response within a certain timeframe. The concerns noted by USFDA are already under remediation by the manufacturing site. Necessary corrective and preventive measures are being taken.”

In the meantime, Zydus Lifesciences shares were 0.13% higher at Rs 1,113.00 on the NSE.